

and a macrometastasis in the group with microinvasive carcinoma (metastatic rate 16%) and two micrometastases in pure DCIS group (metastatic rate 1.4%).

Conclusion: Lymphoscintigraphy is a relatively simple and useful technique to identify the SLN. This method shows a high SLN identification and deserves a special consideration in order to better staging the high-risk group of patients with DCIS.

315

Poster

Predicting non-sentinel-nodes status in patients with metastatic sentinel node: which nomogram?

A. Lombardi¹, S. Maggi¹, M. Lo Russo¹, D. Di Stefano², A. Di Napoli², C. Amanti¹. ¹Università La Sapienza, Unità di Chirurgia Senologica, Rome, Italy; ²Università La Sapienza, Unità di Anatomia Patologica, Rome, Italy

Background: About 35% to 50% of patients with metastatic disease in the Sentinel Lymph Node (SLN) has additional nodal metastases detected at the Completion Axillary Lymph Nodes Dissection (CALND). To identify the individual patient's risk for non-SLN metastases nine statistical methods were described in the recent literature: one from the Breast Service of Memorial Sloan-Kettering Cancer Center (MSKCC), one from Tenon Hospital (France), one from Cambridge (UK), one from Stanford (USA), the Saidi score, the Mayo nomogram and the MDA score (USA), and finally two tools described by Kohrt et al. The outcome of these tools is the predicted probability of Non-SLNs metastasis in positive SLN Biopsy. The aim of this study was to confirm the MSKCC nomogram predictive accuracy in a population of breast cancer patients from Italy, to compare the result with three other tools, the Tenon nomogram, the Stanford and the Cambridge tools and finally, on the base of these results, to review the literature to identify the ideal one. In perspective, the final goal is to avoid CALND in Positive SLN patients with low risk of metastatic Non-SLNs.

Methods: We enrolled in the study 490 consecutive primary breast cancer patients T1/T2 undergone SLNB from October 2004 till July 2009. 130 of these (26%) showed SLN metastasis at Frozen Section (FS) or at the definitive histological examination (40% micro- and 60% macrometastasis). 120 patients, underwent CALND, immediately when SLN positive at the FS, or delayed (about two weeks) in case of False Negative FS. The likelihood of additional nodal metastasis was calculated by the MSKCC tool, the Tenon score, the Stanford and the Cambridge tools and then compared this 'a priori' result with the real non-SLN status using the area under the receiver operating characteristic (ROC) curve. Values greater than 0.70 were considered indicators of good discrimination.

Results: The mean Axillary Lymph Nodes number was 21. 43 of 120 patients (36%) had non-SLN metastasis (10% of the SLN micrometastasis and 57% of the SLN macrometastasis). The area under the curve values were a bit over the threshold of 0.70 for all the four models, but, on the subset of micrometastatic SLNs, all the tools demonstrated themselves inadequate (<0.50).

Conclusions: Despite other works, in our breast cancer population, all the four analysed models showed themselves accurate for predicting nonSLN metastasis. The reported differences may depend on the large variability of the samples about some involved variables (percentage of Micrometastasis, FS performed, T status, lymphovascular invasion, SLNB technique). Micrometastasis, as yet described, represent a peculiar problem and requires caution. We confirm that these models, very accurate in the institution of origin, require a new validation if used on other populations of patients.

316

Poster

The effect of intra-operative frozen section on theatre time

A. Al-Alak¹, S. Govindarajulu², M. Shere², S. Cawthorn², A. Sahu².

¹Cheltenham General Hospital, General Surgery, Cheltenham, United Kingdom; ²Frenchay Hospital, Breast Care Unit, Bristol, United Kingdom

Background: Over the last decade sentinel lymph node biopsy (SLNB) has gained in popularity with more centres carrying out the procedure routinely. One way of assessing lymph node status is intra-operative frozen section (FS) which avoids further axillary procedures and this is the method we have adopted. A criticism of FS has been its possible impact on operating times. The aim of this study was to assess the effect of FS on our total operating times.

Materials & Methods: Data was collected prospectively over a period of six weeks between December 2007 and January 2008. Data included type of procedure, length of operation, time taken for FS, result of the FS as well as time from results to completion of surgery. Data was analysed using Microsoft Excel 2003.

Results: 23 procedures were carried out in the study period of which 15 underwent breast conserving surgery. For this sub-group of patients the average time for FS results was 35 minutes (range 21–57) with two being

positive. Average time from results to completion of surgery was 20 minutes (range – 10–107) with the most delay noted in the two positive cases requiring axillary node clearance. The remaining 8 underwent mastectomy with immediate reconstruction thus FS had no impact.

Conclusion: Although the number of patients is small one may speculate that FS has a very small impact on operating times for those patients undergoing breast conservation surgery. FS also reduces the chances of further axillary dissection thus ultimately saving on theatre time.

317

Poster

Predictive factors of negative axillary dissection after neoadjuvant chemotherapy (NAC): place of a score in decision-making regarding sentinel lymph node after NAC in patients with locally advanced breast cancer

J. Cagnat¹, S. Alran¹, A. Savignoni², J.Y. Pierga³, C. Ngo¹, V. De Margerie¹, Y. Kirova⁴, C. Gautier², A. Vincent-Salomon⁵, R.J. Salmon¹.

¹Institut Curie, Surgery, Paris Cedex 05, France; ²Institut Curie, Statistics, Paris Cedex 05, France; ³Institut Curie, Oncology, Paris Cedex 05, France; ⁴Institut Curie, Radiotherapy, Paris Cedex 05, France; ⁵Institut Curie, Pathology, Paris Cedex 05, France

Background: The main purpose of NAC is to permit conservative breast treatment. In cases where response is good, this conservative approach could be widened to the axilla with sentinel lymph node biopsy (SLNB), further reducing morbidity. This retrospective study identifies the predictive factors of negative axillary dissection (AD) after NAC. These factors, balanced in a score, could be helpful for selecting patients eligible for SLNB post-NAC.

Patients and Methods: 776 patients were treated at the Institut Curie between January, 1990 and December, 1999, for a locally advanced breast cancer (T2-T3). Most of them had a fine-needle aspiration of clinically palpable lymph nodes. All patients received a NAC, followed by breast surgery with AD and radiotherapy according to our protocols. The clinicobiological factors associated with a negative AD were recorded and used in the development of a predictive score of negative AD after NAC.

Results: 461/776 patients (59.4%) had clinically negative lymph nodes before treatment and 315 patients had an axillary lymphadenopathy. After NAC, 326 patients (42%) had a negative AD (pN0). In multivariate analysis, there were three predictive factors of a negative AD: clinically negative lymph nodes before treatment ($p=0.01$), lack of expression of estrogen receptors ($p<0.002$), and a response of the primary tumor clinically $\geq 50\%$ ($p=0.0008$) after NAC. The score we propose allows an accurate estimation of the probability of a negative AD using only preoperative data.

Conclusion: Among patients receiving NAC for locally advanced breast cancer, SLNB should be reserved for patients at low risk of metastatic axillary involvement. The development of a score using three preoperative factors available to the surgeon may be a valuable tool in support of SLNB after NAC.

Data score will be available for the EBCC.

318

Poster

Axillary recurrence rate after negative sentinel lymph node biopsy for invasive breast cancer

J. ten Brinke¹, J.M. Klaase¹, M.F. Lutke Holzik¹. ¹Medisch Spectrum Twente, Surgery, Enschede, The Netherlands

Background: Staging of the axilla by sentinel lymph node biopsy (SLNB) is the treatment of choice in patients with invasive breast cancer without clinical, ultrasound verified, axillary involvement. SLNB is practised in our clinic since 2005. The objective of this retrospective study was to provide data about the success and loco regional control rate of patients with breast cancer staged with SLNB who had a negative SLNB and therefore underwent no axillary lymph node dissection (ALND).

Material and Methods: A retrospective review of all breast cancer patients who underwent a SLNB between January 2005 and December 2008 was performed. Patients with proven invasive breast cancer and without signs of axillary node involvement were enrolled. Lymphatic mapping and identification was performed with subcutaneous injection above the tumour of 2ml. Patent Blue and peritumoral injection of 99m Tc-nanocolloid. All positive SLNBs were followed by an ALND and were excluded from this study. Patients with a negative SLNB received tailor made treatment following the National Guideline Breast Cancer. Patient- and tumour characteristics were collected and analysed.

Results: 412 patients underwent a successful SLNB (91%). About three quarters (72%) of the patients had a negative SLNB. These 296 patients were followed in this study. After a median follow-up of 24.6 months axillary recurrence was found in 3 patients (1.0%). In 6 patients (2.0%) a distant recurrence, without axillary involvement, developed. In 23 patients the SLNB showed only presence of submicrometastases (<0.2 mm) and were